[Image courtesy of Robeauté]

[照片由Robeaute提供]

Robeauté

长袍

announced today that it raised $28 million to support the development of its neurosurgical microrobot technology.

今天宣布筹集2800万美元用于支持其神经外科微型机器人技术的发展。

Plural, Cherry Ventures and Kindred Ventures led the financing. Other investors included LocalGlobe and Think.Health, plus existing investors APEX Ventures, participated. Brainlab contributed a strategic investment.

多元化、Cherry Ventures和同类企业主导了融资。其他投资者包括LocalGlobe和Think。Health，加上现有投资者APEX Ventures，都参加了。Brainlab提供了一项战略投资。

Paris-based Robeauté plans to use the funds to continue development and start human trials in 2026. It intends to set up U.S. operations ahead of FDA approval and full go-to-market efforts as well.

总部位于巴黎的罗伯奥计划利用这些资金继续开发，并于2026年开始人体试验。它打算在FDA批准之前建立美国业务，并全力投入市场。

The company develops microrobots that come in at the size of a grain of rice. They can move along curved routes through the brain’s extracellular matrix to safely reach multiple sites of interest and carry out the required tasks. According to a news release, the company’s tiny, modular medical devices can embark on specific missions depending on the pathology..

该公司开发了一种米粒大小的微型机器人。。根据一份新闻稿，该公司的微型模块化医疗设备可以根据病理情况执行特定任务。。

Robeauté says the devices could prove ideal for delivering molecules, implanting electrodes and collecting cell or live-data samples through sensors. This could transform the understanding and ability to treat neuropathologies, the company says. The technology is currently in animal studies as a biopsy tool, with the company’s sights set on later use for treatment and real-time monitoring..

罗伯特·奥特（Robeauté）说，这些设备可能被证明是传递分子、植入电极以及通过传感器收集细胞或活体数据样本的理想选择。该公司表示，这可能会改变对神经病理学的理解和治疗能力。该技术目前正在动物研究中作为活检工具，该公司的目标是以后用于治疗和实时监测。。

Brainlab’s strategic investment also supports the company’s entrance into the U.S. It plans to pursue FDA approval before pursuing a regulatory nod in Europe.

Brainlab的战略投资也支持该公司进入美国。它计划在欧洲寻求监管点头之前先获得FDA的批准。

“We’re creating microrobots that will bring unparalleled access to the brain with personalized, precision medicine that can transform treatments and patient outcomes,” Bertrand Duplat, Robeauté co-founder and CEO said. “Over the past eight years, we’ve built a world-class team of experts, filed over 50 patents and commenced animal trials.

罗伯特·奥特（Robeauté）联合创始人兼首席执行官伯特兰·杜普拉特（BertrandDuplat）表示：“我们正在创造微型机器人，通过个性化、精准的医学手段，为大脑提供无与伦比的通路，从而改变治疗和患者的预后。”。“在过去的八年中，我们建立了一支世界级的专家团队，申请了50多项专利，并开始了动物试验。

This new funding from some of Europe’s leading investors will take us to the next level as part of our mission to empower neurosurgeons or neurospecialists with the tools to make a difference.”.

这项来自欧洲一些主要投资者的新资金将把我们带到一个新的水平，作为我们使命的一部分，赋予神经外科医生或神经专科医生以有所作为的工具。”。